Program overview

Immunotherapy stage IV NSCLC

Time: 12:15 - 12:35 CET

Discussion & Take-home

Time: 12:05 - 12:15 CET

Unresectable NSCLC

Time: 11:45 - 12:05 CET

Resectable NSCLC

Time: 11:25 - 11:45 CET

Pathology & biomarkers

Time: 11:10 - 11:25 CET

2025 in review

Time: 11:09 - 11:10 CET

Coffee break – Meet sponsors

Time: 10:45 - 11:09 CET

Other oncogene addictions

Time: 10:25 - 10:45 CET

Cases second vote & take-home

Time: 10:15 - 10:25 CET

Discussion

Time: 10:00 - 10:15 CET

Q&A

Time: 09:50 - 10:00 CET

Recent news from ALK clinical trials

Time: 09:35 - 09:50 CET

Cases: ALK translocation

Time: 09:30 - 09:35 CET

Recent news from EGFR clinical trials

Time: 09:15 - 09:30 CET

Hot topic 2025: Oncogene addicted stage IV NSCLC

Time: 09:09 - 09:09 CET

Break & Dessert

Time: 20:35 - 20:55 CET

Closure

Time: 21:55 - 22:00 CET

Tackling NSCLC with EGFR exon 20 insertion mutation

Time: 21:25 - 21:55 CET

Prof. Dr. Sebahat Ocak (Mont-Godinne, UCL, Namur)

New options for advanced EGFR mutant NSCLC

Time: 20:55 - 21:25 CET

Dr. Antonio Passaro (Eur Institute Oncology, Milan, Italy)

First-line dual immunotherapy for metastatic NSCLC

Time: 20:05 - 20:35 CET

Prof. Dr. Kostas Syrigos (University of Athens, Greece)

Neoadjuvant chemo-immunotherapy: Belgian experience

Time: 19:35 - 20:05 CET

Prof. Dr.  Christophe Dooms (Gasthuisberg & KUL, Leuven)

Opening

Time: 19:30 - 19:35 CET

Prof. Dr. Johan Vansteenkiste, UZ Leuven

Registration & Buffet

Time: 19:00 - 19:30 CET

Closure

Time: 12:55 - 13:00 CET

SCLC & mesothelioma

Time: 12:35 - 12:55 CET

Cases: EGFR mutation

Time: 09:10 - 09:15 CET

Introduction

Time: 09:00 - 09:08 CET

Welcome & Registration

Time: 08:30 - 09:00 CET